Muticentre study to investigate the efficacy of scalp cooling for the prevention of Myocet/cyclofosfamide-induced alopecia in patients with metastatic breast cancer. MyCap study

Muticentre study to investigate the efficacy of scalp cooling for the prevention of Myocet/cyclofosfamide-induced alopecia in patients with metastatic breast cancer. MyCap study - MyCap

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON35380

Enrollment

Registered

2011-11-29

Start date

2012-02-20

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

haaruitval t.g.v. chemotherapie alopecia hair loss

Interventions

Treatment with or without scalp cooling. Trichometry.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Female breast cancer patients, treated with Myocet and cyclophosphamide containing chemotherapy. * Life expectancy * 12 weeks. * ECOG performance scale * 2. * Age 18 years and above.

Exclusion criteria

Exclusion criteria: * Allopecia prior to start of the study. * Simultaneously or shortly after study start: planned skull irradiation (if allopecia is expected). * Severely disturbed liver enzymes (see protocol for details). * Hair extensions

Design outcomes

Primary

Measure	Time frame
Allopecia measured by trichometry.	—

Secondary

Measure	Time frame
Subjective severity of allopecia.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)